We must learn from the HIV epidemic and ensure that affordable prices are in place so that the millions with hepatitis C infection can get new drugs that appear to be a cure...There are 185 million people in the world chronically infected with hepatitis C virus, which...can cause liver cancer and cirrhosis. Around 350,000 people die as a result every year...The recent breakthrough in treatment is...really good news...The leader of the pack is Gilead's sofosbuvir...Janssen [part of Johnson & Johnson] and Bristol Myers-Squibb are hard on their heels...[With] most of the sufferers in middle-income countries and prices being set at very high levels...those who watched the delay in getting HIV treatment to poor countries think it is time to start agitating for access to these medicines...Médecins du Monde, in a new report,...looks at the need and what companies like Gilead say they will do about it. The authors are not, as yet, impressed. [full report refers to AbbVie, and to following countries: China, Brazil, Thailand, Indonesia, Georgia, France, Dem. Rep. of Congo, Cameroon]